Celldex Therapeutics CFO plans March 2027 retirement

Q: What executive change did Celldex Therapeutics (CLDX) disclose?

Celldex Therapeutics disclosed that Sam Martin, Senior Vice President and Chief Financial Officer, plans to retire effective on or about March 31, 2027. He will remain in his role until that date or until a successor assumes the CFO position.

Q: How long has Celldex (CLDX) CFO Sam Martin been with the company?

Sam Martin joined Celldex in April 2009 and has served as Chief Financial Officer since July 2017. This means his planned retirement would follow a lengthy tenure at the company, including nearly a decade in the CFO role.

Q: Is Celldex Therapeutics (CLDX) searching for a new CFO?

Celldex stated that it has initiated a search for a new Chief Financial Officer. During this process, Sam Martin intends to continue in the CFO role to help ensure a smooth handoff of responsibilities to his successor.

Q: Will Celldex (CLDX) CFO Sam Martin remain during the transition period?

Yes. Sam Martin intends to remain as Chief Financial Officer through March 31, 2027, or until his successor begins serving. This arrangement is intended to provide continuity and support a smooth transition of his responsibilities.

Celldex Therapeutics, Inc. reported that Sam Martin, its Senior Vice President and Chief Financial Officer, has informed the company of his plans to retire effective on or about March 31, 2027.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Celldex Therapeutics, Inc. reported that Sam Martin, its Senior Vice President and Chief Financial Officer, has informed the company of his plans to retire effective on or about March 31, 2027. Martin joined Celldex in April 2009 and has served as Chief Financial Officer since July 2017.

The company has begun a search for a new Chief Financial Officer. To support continuity, Martin intends to continue serving as CFO through March 31, 2027, or until an appointed successor begins serving in that role, to help ensure a smooth transition of his responsibilities.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Retirement notice date: July 10, 2026 Planned retirement effective date: on or about March 31, 2027 Company tenure start: April 2009 +1 more

4 metrics

Retirement notice date July 10, 2026 Date Sam Martin informed Celldex of his plans to retire as Senior Vice President and CFO

Planned retirement effective date on or about March 31, 2027 Target effective date for Sam Martin’s retirement as CFO

Company tenure start April 2009 Month and year Sam Martin joined Celldex Therapeutics

CFO tenure start July 2017 Month and year Sam Martin began serving as Chief Financial Officer

Key Terms

Emerging growth company, Form 8-K, Nasdaq Capital Market, Inline XBRL

4 terms

Emerging growth company regulatory

"Emerging growth company Item 5.02."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Form 8-K regulatory

"20549 FORM 8-K July 10, 2026 Celldex Therapeutics"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

Nasdaq Capital Market market

"Common Stock, par value $.001 | CLDX | Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

Inline XBRL technical

"104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive change did Celldex Therapeutics (CLDX) disclose?

Celldex Therapeutics disclosed that Sam Martin, Senior Vice President and Chief Financial Officer, plans to retire effective on or about March 31, 2027. He will remain in his role until that date or until a successor assumes the CFO position.

When will Celldex (CLDX) CFO Sam Martin’s retirement become effective?

Sam Martin’s retirement as Celldex’s CFO is expected to be effective on or about March 31, 2027. Until then, he plans to continue serving as Chief Financial Officer to support an orderly transition to his eventual successor.

How long has Celldex (CLDX) CFO Sam Martin been with the company?

Sam Martin joined Celldex in April 2009 and has served as Chief Financial Officer since July 2017. This means his planned retirement would follow a lengthy tenure at the company, including nearly a decade in the CFO role.

Is Celldex Therapeutics (CLDX) searching for a new CFO?

Celldex stated that it has initiated a search for a new Chief Financial Officer. During this process, Sam Martin intends to continue in the CFO role to help ensure a smooth handoff of responsibilities to his successor.

Will Celldex (CLDX) CFO Sam Martin remain during the transition period?

Yes. Sam Martin intends to remain as Chief Financial Officer through March 31, 2027, or until his successor begins serving. This arrangement is intended to provide continuity and support a smooth transition of his responsibilities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/15/2026 - 04:07 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 10, 2026

Celldex Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		000-15006		13-3191702
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Perryville III Building, 53 Frontage Road, Suite 220,

Hampton, New Jersey 08827

(Address of principal executive offices) (Zip Code)

(908) 200-7500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $.001	CLDX	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the “Company”), notified the Company of his plans to retire effective on or about March 31, 2027. Mr. Martin joined the Company in April 2009 and has served as Chief Financial Officer since July 2017. The Company has initiated a search for a new Chief Financial Officer. To ensure a smooth transition of his responsibilities, Mr. Martin intends to continue to serve the Company as Chief Financial Officer through March 31, 2027 or until such earlier time as his successor begins to serve in such capacity.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CELLDEX THERAPEUTICS, INC.

Dated: July 15, 2026	By:	/s/ Anthony Marucci
	Name:	Anthony Marucci
	Title:	President and Chief Executive Officer

-3-

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents